REVIEW

The role of cDC1s *in vivo*: CD8 T cell priming through cross-presentation [version 1; peer review: 3 approved]

Derek Theisen¹, Kenneth Murphy^{1,2}

¹Department of Pathology and Immunology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA

²Howard Hughes Medical Institute, Washington University in St. Louis School of Medicine, St. Louis, MO, USA

V1 First published: 01 Feb 2017, 6(F1000 Faculty Rev):98
<https://doi.org/10.12688/f1000research.9997.1>

Latest published: 01 Feb 2017, 6(F1000 Faculty Rev):98
<https://doi.org/10.12688/f1000research.9997.1>

Abstract

The cDC1 subset of classical dendritic cells is specialized for priming CD8 T cell responses through the process of cross-presentation. The molecular mechanisms of cross-presentation remain incompletely understood because of limited biochemical analysis of rare cDC1 cells, difficulty in their genetic manipulation, and reliance on *in vitro* systems based on monocyte- and bone-marrow-derived dendritic cells. This review will discuss cross-presentation from the perspective of studies with monocyte- or bone-marrow-derived dendritic cells while highlighting the need for future work examining cDC1 cells. We then discuss the role of cDC1s as a cellular platform to combine antigen processing for class I and class II MHC presentation to allow the integration of “help” from CD4 T cells during priming of CD8 T cell responses.

Keywords

Dendritic cell , monocyte-derived dendritic cells , T cell response

Open Peer Review

Approval Status

	1	2	3
version 1 01 Feb 2017			

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Caetano Reis e Sousa**, The Francis Crick Institute, London, UK
2. **Terri M. Laufer**, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
Philadelphia Veterans Affairs Medical Center, Philadelphia, USA
3. **Paul Roche**, National Cancer Institute, National Institutes of Health, Bethesda, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Kenneth Murphy (KMurphy@pathology.wustl.edu)

Competing interests: The authors declare that they have no competing interests.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2017 Theisen D and Murphy K. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Theisen D and Murphy K. **The role of cDC1s *in vivo*: CD8 T cell priming through cross-presentation [version 1; peer review: 3 approved]** F1000Research 2017, 6(F1000 Faculty Rev):98 <https://doi.org/10.12688/f1000research.9997.1>

First published: 01 Feb 2017, 6(F1000 Faculty Rev):98 <https://doi.org/10.12688/f1000research.9997.1>

Introduction

Dendritic cells (DCs) are a distinct lineage of innate immune cells that was originally defined based on its unique stellate morphology and ability to prime T cell responses¹⁻³. DCs broadly segregate into four groups, plasmacytoid DCs (pDCs), classical DCs (cDCs), Langerhans cells, and monocyte-derived DCs (moDCs) based on function and surface markers. pDCs are potent producers of type I interferons in response to viral pathogens⁴⁻⁷. cDCs themselves are divided into two lineages, recently renamed⁸ as cDC1 (CD8 α ⁺ DCs) and cDC2 (CD8 α ⁻ DCs). The cDC2 lineage is heterogeneous and expresses the *Irf4* transcription factor⁹⁻¹¹. Notch 2-dependent cDC2s are required for IL-23 production in response to *Citrobacter rodentium* infection^{12,13}, while a separate *Klf4*-dependent subset of cDC2s is required for type II responses to house dust mite antigen and *Schistosoma mansoni* infection¹⁴. By contrast, cDC1 cells require the *Irf8*^{10,15,16} and *Batf3* transcription factors^{10,16,17} and produce the IL-12 necessary for protection against *Toxoplasma gondii*^{18,19}. They are also the subset involved in priming CD8 T cell responses to tumors and virally infected cells through cross-presentation^{17,20}. All cDCs *in vivo* arise from a common DC progenitor (CDP) in the bone marrow²¹.

Cultures of monocytes in GM-CSF and IL-4 are able to produce DC-like cells, distinct from those that develop from the CDP²², termed monocyte-derived DCs (moDCs), in large numbers²³. Similar cells that derive from cultures of whole bone marrow with GM-CSF with or without IL-4 *in vitro* have been referred to as “moDCs”, despite the uncertainty of the origin, or bone-marrow-derived DCs (BMDCs). BMDCs have been the basis for many studies aimed at understanding the properties of cDCs^{24,25}. Recent studies have shown that these cultures are actually heterogeneous and that it may not be appropriate to refer to the cells that are generated as moDCs, since many display macrophage characteristics and the precursor to the DC-like cells from whole bone marrow is not known²⁶. Some investigators object to the use of the term moDC for *in-vitro*-derived cells from whole bone marrow since it is misleading with regard to their development; however, it has been argued that the DC-like cells that develop from GM-CSF cultures develop from monocytes²⁷. The term BMDC can also lead to confusion, since DCs can also be derived from bone marrow cultures with fms-related tyrosine kinase 3 ligand (Flt3L) and produce cells that are distinct from those produced in GM-CSF cultures²⁷. Therefore, in this review, we will refer to cells generated from monocytes as moDCs and cells generated from whole bone marrow GM-CSF cultures as GMDCs. Conceivably, both may be derived from monocytes and distinct from *in-vivo*-derived cDCs.

In this review, we will first highlight new discoveries regarding cross-presentation and discuss how molecular mechanisms governing cross-presentation by cDC1s may be distinct from the cross-presentation pathways identified in moDCs or GMDCs *in vitro*. We will then describe how cDC1s initiate and maintain anti-viral responses, including through their interactions with CD4 T cells.

Molecular mechanisms of cross-presentation

Cross-presentation is the process by which exogenous antigens are taken up by antigen-presenting cells and presented on major

histocompatibility class I (MHCI)²⁸. cDC1s are the unique DC subset specialized in cross-presentation *in vivo*²⁰. The molecular mechanisms specific to DCs that govern cross-presentation have been the subject of a large body of work over the past decade²⁹, with much of the early work on cross-presentation carried out in macrophages³⁰⁻³², though the majority of our understanding of cross-presentation is based on experiments carried out using GMDCs. GMDCs are generated from bone marrow cultures with GM-CSF alone or GM-CSF with IL-4 originally developed in the early 1990s²⁴⁻²⁶. While these cells can cross-present *in vitro*, it is unlikely that these are the cells that operate *in vivo*, since *Batf3*^{-/-} mice that lack cDC1s fail to mount CD8 T cell responses to challenges requiring cross-presentation¹⁷. However, *Batf3*^{-/-} mice can generate moDCs that are able to cross-present normally *in vitro*³³, indicating that any moDCs that may develop *in vivo* do not compensate for the loss of cDC1s for *in vivo* cross-presentation.

Surprisingly little work has been done to analyze cross-presentation in DCs derived from bone marrow cultures with Flt3L. DCs that resemble splenic cDC1 and cDC2 by surface markers can be generated in large numbers in bone marrow cultures with Flt3L^{34,35}. These cells are able to present antibody-targeted antigens and activate T cells to a similar extent as cDCs of the same lineage derived *in vivo*³⁶. Also, Flt3L-derived DCs express *Rab43*, a molecule necessary for cross-presentation in *in vivo* cDC1s but not moDCs³⁷. While more studies may be needed to compare the cross-presentation efficiency of Flt3L-derived DCs to *in-vivo*-generated cDCs, Flt3L-derived DCs are arguably more appropriate for *in vitro* studies of DC function than GMDCs. Nonetheless, the examination of macrophages and GMDCs has been useful for identifying the components of two major cross-presentation pathways, the cytosolic and vacuolar pathways.

In the cytosolic pathway, exogenous antigens that are taken up into phagosomes are exported into the cytosol to enter the traditional proteasome- and TAP-dependent MHCI presentation pathway^{32,38,39}. The cytosolic pathway is dependent on the reduced acidification of phagosomes produced by the activity of NADPH oxidase Nox2, leading to delayed antigen degradation^{40,41}. Recruitment and localization of NOX2 components was determined to be regulated by the activities of Rac2 and Rab27a^{41,42}. Phagosomal alkalization has also been demonstrated to involve Rab3c (a marker of recycling vesicles⁴³), Rab34 (an LPS-regulated protein that can delay phagolysosomal fusion⁴⁴), and TFEB (a transcription factor that can negatively regulate cross-presentation⁴⁵). The delay in antigen degradation caused by phagosomal alkalization acts to allow antigens to move into the cytosol, possibly through channels such as Sec61, promoting antigen processing and presentation through the normal MHCI pathway⁴⁶. These pathways have mainly been shown to act in phagosomes containing latex beads, raising the question of whether this process is specific to uptake of beads or if antigens that bind different receptors are processed through similar mechanisms.

NOX2 has been shown to play a role in cross-presentation *in vivo*^{40,42}, suggesting that phagosomal alkalization may also be important for cross-presentation by cDC1s. However, the magnitude of the contribution of this pathway is limited, as loss of NOX2 activity

decreased cross-presentation of antibody-targeted antigen only by about 50%⁴⁰. The remainder of the molecules in the cytosolic pathway, including Rac2, Rab27a, Rab3c, Sec61, TFEB, and Rab34, have not been examined in *in vivo* cDCs^{41–45}. Genetic studies with mouse models will be necessary to determine the importance of these molecules and the cytosolic pathway in general to cross-presentation *in vivo*.

The vacuolar pathway involves the loading of MHCI molecules by antigens processed directly within endosomes without transport to the cytosol and is independent of TAP and the proteasome^{47,48}. One molecule linked to the vacuolar pathway is the insulin-regulated aminopeptidase (IRAP)⁴⁹. IRAP can trim peptides in DC phagosomes to lengths appropriate for loading into MHCI molecules⁴⁹, similar to the action of endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP) in the endoplasmic reticulum⁵⁰. The role of IRAP *in vivo* remains unclear. Although an early study detailing the mechanism of IRAP was conducted using *in vitro* GMDCs, IRAP-deficient mice were also shown to have reduced cross-presentation⁴⁹. However, a subsequent study concluded that IRAP was not required for cross-presentation of soluble OVA or OVA-coated splenocytes by splenic cDC1s *in vitro*, suggesting that IRAP may not play a role in cDC1-mediated cross-presentation⁵¹. But another study, using OVA-expressing yeast *in vitro*, showed that IRAP is recruited to endosomes in cDC1 cells and that cross-presentation is reduced in IRAP-deficient cDC1s⁵². Conceivably, the use of differing forms of antigen underlies some of these variances. While the ability of cDC1 cells to cross-present is not solely due to their ability to capture antigens^{53,54}, it is plausible that distinct antigen internalization and processing pathways are used for different forms of antigen. For example, cell-associated and soluble antigens are not cross-presented equally and cDC2s, which do not cross-present *in vivo*²⁰, have the capacity to present soluble antigens *in vitro*^{52,54}. Therefore, work is still needed to compare cross-presentation of different antigens by cDC1s and cDC2s *in vitro* to find a system that mimics *in vivo* models where only cDC1s are able to cross-present. Developing standardized assays for the field through careful comparison of DC subsets may help to eliminate confusion between whether or not molecules are necessary for cross-presentation *in vivo* as in the case of IRAP.

Presentation through the vacuolar pathway requires the loading of MHCI molecules within endosomes. The molecule Sec22b was described in GMDCs to regulate the movement of the peptide-loading complex to endosomes⁵⁵. It has also been shown that GMDCs contain pools of MHCI in endosomal recycling compartments marked by Rab11a⁵⁶. A model has been proposed where TLR signals induce MHCI movement from these intracellular pools to phagosomes, where they meet antigen and the peptide-loading complex machinery brought by Sec22b⁵⁶. A second proposed model involves CD74, the MHCI invariant chain, which was also shown to control the movement of MHCI to endosomes and to regulate cross-presentation *in vivo*⁵⁷. CD74 acts in both splenic cDC1s and GMDCs, meaning CD74 and IRAP are the two molecules shown to be involved in the vacuolar pathway of cross presentation in cDC1s^{52,57}. However, as with the cytosolic pathway, many gaps still remain in our understanding of what proteins and signals are involved in regulating the cross-presentation ability of cDC1s.

Role of moDCs *in vivo*

The discovery that moDCs cannot compensate for the loss of cross-presentation by cDC1s *in vivo* has called into question their relevance *in vivo*³³. Bone marrow cultured with GM-CSF produces a heterogeneous population of CD11c⁺ MHCII⁺ cells which contain functionally distinct macrophages and DCs²⁶. While moDCs have a stellate morphology, express the cDC-specific ZBTB46 transcription factor⁵⁸, and can cross-present cell-associated antigens, they do so in a manner distinct from *ex vivo* cDC1 cells^{33,51}.

Further, recent work has called into question if moDCs exist *in vivo*. Studies of moDCs started with the observation that transferred monocytes are able to generate CD11c⁺ DC-like cells *in vivo*²². These moDCs have been observed in numerous models including viral infections⁵⁹, alum-OVA immunization⁶⁰, arthritis⁶¹, and house dust mite exposure⁶². They can be distinguished from cDCs *in vivo* by expression of CD64 and MAR-1^{60,62} and are dependent on CCR2 and CD115 (MCSF-R)^{60,63}. However, it is unclear whether the moDCs identified in these studies *in vivo* are equivalent to those generated with GM-CSF and IL-4 *in vitro*. Recent lineage tracing has suggested that the inflammatory cells that develop during house dust mite challenge lack expression of the cDC marker ZBTB46⁵⁸ and instead express the macrophage-specific transcription factor MafB^{64,65}, suggesting that these cells are not moDCs but rather monocyte-derived macrophages. Furthermore, others have shown little functional difference among moDCs, monocyte-derived macrophages, myeloid-derived suppressor cells, and immature monocytes^{8,66,67}, also suggesting that *in vivo* moDCs may actually be monocyte-derived macrophages. In addition, no *in vivo* model has yet to be described where moDCs are required for cross-presentation. Lineage tracing of *in vivo* moDCs and comparisons to *in vitro*-derived GMDCs will be necessary to determine whether GM-CSF cultures are an appropriate model to study DC function. Owing to the observed differences between GMDCs and cDC1s, studies of cross-presentation *in vitro* should rely on either *ex vivo* cDCs or Flt3L-derived DCs to more appropriately model how cross-presentation occurs *in vivo*.

Cross-presentation during viral infections

Though cDC1s are the major cell that appears to carry out cross-presentation for expanding CD8 T cells *in vivo*²⁰, many cells are able to present antigens on MHCI to CD8 T cells⁶⁸. Therefore, it is unclear whether cross-presentation is the only pathway used in priming CD8 T cells to pathogens, or alternately whether direct presentation by infected cells might contribute in some settings. Indeed, the cell type responsible for T cell priming and the pathway of antigen processing may vary with the pathogen and could depend on factors such as viral tropism and the time after infection^{69–71}. For example, using DC-tropic vaccinia virus expressing an extended OVA peptide that could not be cross-presented, Xu *et al.* demonstrated that direct presentation is sufficient for generating a CD8 T cell response⁶⁹. However, during infection with mouse cytomegalovirus, another DC-tropic virus, the predominant T cell clones react to epitopes that were presented through cross-presentation^{70,71}. It is likely that both direct and cross-presentation can contribute in priming CD8 T cell responses and that the predominant form of presentation may depend on the stage of infection. Early during infection, antigen presentation requires viral replication, suggesting

direct presentation is playing a role; however, late during infection most presentation occurs by uninfected DCs through cross-presentation⁷² (Figure 1). Imaging of T cells and cDC1s during vaccinia virus infection showed a similar phenomenon and it was observed that multiple DC subsets could prime CD8 T cell responses early during infection; however, later in infection CD8 T cells interacted with only XCR1-expressing cDC1s⁷³. cDC1s are also essential for priming CD8 T cell responses during secondary infections and generating T resident memory cells, a process recently shown to depend on cross-presentation^{74,75}.

In lymph nodes, cDC1s can be separated into two categories of migratory and resident DCs that are developmentally related⁷⁶, either of which could be involved in the presentation of antigen to CD8 T cells during an infection. Tracking of migratory DCs from the skin during herpes simplex virus (HSV) infection has shown that CD8 T cell priming occurs in lymph nodes and movement of migratory DCs from the skin is required for priming to occur⁷⁷.

Then in the lymph node, antigens acquired by migratory DCs can be transferred to lymph-node-resident DCs for presentation to CD8 T cells⁷⁷ (Figure 1C). These results imply that there may be two distinct priming events: an initial priming from migratory cDC1s that directly captured antigen and then a secondary priming that occurs after antigen has been transferred to resident cDC1s. Imaging of the anti-viral response to HSV suggested that CD4 T cells are primed before CD8 T cells and that they interact with migratory DCs, while CD8 T cells interact with resident cDC1s in the lymph node⁷⁸. However, others have demonstrated that antigen-specific CD8 T cells preferentially interact with migratory cDC1s^{79,80}. These results raise the question of whether all CD8 T cell priming occurs through migratory cDC1s, which are directly exposed to antigens, or through resident cDC1s, which can present their antigens through either cross-presentation^{73,77} or cross-dressing, a process by which loaded MHC I is transferred between different cells⁸¹. Conceivably, early CD8 and potentially CD4 T cell priming is mediated by direct presentation from migratory cDC1s, since they encounter

Figure 1. Model for CD8 T cell priming by resident classical CD8 α ⁺ dendritic cells (cDC1s). (A) Antigen is captured by migratory cDC1s or CD11b⁺ cDCs (cDC2s) at the site of infection by either direct infection or phagocytosis. (B) After antigen capture, migratory cDC1s or cDC2s with antigen then migrate to the draining lymph node, where they prime naïve antigen-specific CD4 and possibly CD8 T cells through major histocompatibility (MHC):T cell receptor (TCR) interactions. (C) Migratory cDCs transfer antigens to resident cDC1s through either "cross-dressing", the process by which loaded MHC I is transferred between cell membranes, or by transferring the antigen itself, which is then taken up by the resident cDC1s for cross-presentation. (D) Resident cDC1s receive "help" through CD40:CD40L interactions with CD4 T cells, which allow them to prime antigen-specific naïve CD8 T cells through MHC I:TCR interactions. Mig-DC, migratory dendritic cell.

antigen first, and then later CD8 T cell priming occurs after antigen transfer to and cross-presentation by lymph-node-resident cDC1s (Figure 1A and D).

CD4 T cells and cDC1s

For many pathogens, DCs alone are not enough to prime a CD8 T cell response. CD4 T cells and type I interferons have been shown to be involved in the “help” reaction, which stimulates DCs and enables them to prime CD8 T cells^{82,83}. Early work on cross-presentation showed that CD4 T cell help to DCs is necessary for the generation of a CD8 T cell response against cell-associated antigens⁸². This help is mediated through interactions between CD40 on DCs and CD40L on CD4 T cells^{84–86}. These results describe a “bridge” model, where CD4 T cells and CD8 T cells interact with the same dendritic cell, albeit likely at different times, in order to properly prime a cytotoxic T cell response^{78,85}. This suggests that CD4 T cells must be activated prior to CD8 T cells, likely by migratory cDCs, in order for them to act on cDC1s through CD40L to help induce CD8 T cell priming (Figure 1B and D).

Questions remain as to whether the interaction between cDC1s and CD4 T cells is antigen specific. Initial studies that showed that CD4 T cell help for CD8 T cell priming required cognate CD4 T cell interactions⁸². However, later it was suggested that CD40 signaling was sufficient to provide help, even when DCs lack MHCII⁸⁵. *In vitro* analysis of presentation by DC subsets using antibody-targeted antigen implied that cDC1s were relatively poor in antigen presentation to CD4 T cells relative to cDC2s, while cDC2s were adept at activating CD4 T cells *in vitro*^{36,87}. This leads to the question of whether cDC1s use MHCII presentation solely to obtain help from previously activated CD4 T cells for CD8 T cell priming or, alternatively, whether cDC1s can also prime naïve CD4 T cells. A recent study has shown that CD8 T cells cluster with cDC1s, while CD4 T cells cluster with cDC2s during OVA immunization⁸⁸, suggesting that T cell priming may be DC-subset specific. However, late during viral infection both cDC1 and cDC2 subsets have the capacity to activate CD4 T cells⁷⁹. In addition, both CD4 and CD8 T cell priming against insulin in non-obese diabetic mice is decreased in the absence of cDC1s⁸⁹. Since CD4 T cells were shown to be primed first by migratory DCs⁷⁸, it is possible that migratory cDC1s prime the CD4 T cells that later help lymph-node-resident cDC1s induce CD8 T cell priming (Figure 1B and D). Further studies will be necessary to determine to what extent each DC subset contributes to T cell priming in different infection contexts.

Conclusion

cDC1s are the predominant cross-presenting cells functioning in CD8 T cell priming *in vivo*²⁰. Recent imaging studies suggest

that cDC1s also function as a platform for CD4 T cell help during viral infections^{74,78}, likely through CD40–CD40L interactions^{84,85}. However, it remains unclear whether cDC1s can also prime naïve CD4 T cells or whether they receive only help from them^{36,79,82,89}. More sophisticated *in vivo* models will need to be generated in order to determine the role of cDC1s in priming CD4 T cell responses *in vivo* in order to further distinguish the unique roles of DC subsets.

Transcriptional profiling has suggested that moDCs may not be a functional cross-presenting DC subset *in vivo*³³ and at least in one setting may represent monocyte-derived macrophages⁶⁵. Many molecules described previously to be involved in cross-presentation were evaluated in the context of GMDCs and need to be examined in the context of cDC1s^{41–45}. Recent advances in DC biology have allowed for the conditional deletion of genes in cDC1s through the use of XCR1-cre⁹⁰ and analysis of transcriptional differences between DC subsets⁹¹. Examining molecules described in moDCs also in cDC1s and studying other cDC1-specific genes will aid in our understanding of how cross-presentation against viral and cancer antigens occurs and may provide more insight into whether moDCs are a true DC subset *in vivo*. Elucidating the mechanisms by which cDC1s activate CD8 T cells and the mechanisms underlying the various interactions between DC subsets and T cells should be of value in designing DC-based cancer vaccines.

Abbreviations

BMDC, bone-marrow-derived dendritic cell; cDC, classical dendritic cell; CDP, common dendritic cell progenitor; DC, dendritic cell; Flt3L, fms-related tyrosine kinase 3 ligand; GMDC, GM-CSF-derived dendritic cell; HSV, herpes simplex virus; IRAP, insulin-regulated aminopeptidase; MHCI, major histocompatibility class I; MHCII, major histocompatibility class II; moDC, monocyte-derived dendritic cell; pDC, plasmacytoid dendritic cell.

Competing interests

The authors declare that they have no competing interests.

Grant information

The author(s) declared that no grants were involved in supporting this work.

Acknowledgements

We thank Prachi Bagadia, Carlos Briseño, and Vivek Durai for their contributions to this review.

References

1. Steinman RM, Cohn ZA: **Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution.** *J Exp Med.* 1973; **137**(5): 1142–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. Steinman RM, Witmer MD: **Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice.** *Proc Natl Acad Sci U S A.* 1978; **75**(10): 5132–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Nussenzweig MC, Steinman RM, Gutchinov B, *et al.*: **Dendritic cells are accessory cells for the development of anti-trinitrophenyl cytotoxic T lymphocytes.** *J Exp Med.* 1980; **152**(4): 1070–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Perussia B, Fanning V, Trinchieri G: **A leukocyte subset bearing HLA-DR antigens is responsible for in vitro alpha interferon production in response to viruses.** *Nat Immun Cell Growth Regul.* 1985; **4**(3): 120–37.
[PubMed Abstract](#)
5. Cella M, Jarrossay D, Facchetti F, *et al.*: **Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon.** *Nat Med.* 1999; **5**(8): 919–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Siegal FP, Kadowaki N, Shodell M, *et al.*: **The nature of the principal type 1 interferon-producing cells in human blood.** *Science.* 1999; **284**(5421): 1835–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Asselin-Paturel C, Boonstra A, Dalod M, *et al.*: **Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology.** *Nat Immunol.* 2001; **2**(12): 1144–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
8. Guillemin M, Ginhoux F, Jakubzick C, *et al.*: **Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny.** *Nat Rev Immunol.* 2014; **14**(8): 571–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Suzuki S, Honma K, Matsuyama T, *et al.*: **Critical roles of interferon regulatory factor 4 in CD11b^{hi}CD8alpha^{hi} dendritic cell development.** *Proc Natl Acad Sci U S A.* 2004; **101**(24): 8981–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Tamura T, Tailor P, Yamaoka K, *et al.*: **IFN regulatory factor-4 and -8 govern dendritic cell subset development and their functional diversity.** *J Immunol.* 2005; **174**(5): 2573–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Jaitin DA, Kenigsberg E, Keren-Shaul H, *et al.*: **Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types.** *Science.* 2014; **343**(6172): 776–779.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
12. Lewis KL, Caton ML, Bogunovic M, *et al.*: **Notch2 receptor signaling controls functional differentiation of dendritic cells in the spleen and intestine.** *Immunity.* 2011; **35**(5): 780–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Satpathy AT, Briseño CG, Lee JS, *et al.*: **Notch2-dependent classical dendritic cells orchestrate intestinal immunity to attaching-and-effacing bacterial pathogens.** *Nat Immunol.* 2013; **14**(9): 937–48.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Tussiwand R, Everts B, Grajales-Reyes GE, *et al.*: **Klf4 expression in conventional dendritic cells is required for T helper 2 cell responses.** *Immunity.* 2015; **42**(5): 916–28.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Aliberti J, Schulz O, Pennington DJ, *et al.*: **Essential role for ICSBP in the in vivo development of murine CD8alpha⁺ dendritic cells.** *Blood.* 2003; **101**(1): 305–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Schiavoni G, Mattei F, Sestili P, *et al.*: **ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha⁺ dendritic cells.** *J Exp Med.* 2002; **196**(11): 1415–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Hildner K, Edelson BT, Purtha WE, *et al.*: **Batf3 deficiency reveals a critical role for CD8alpha⁺ dendritic cells in cytotoxic T cell immunity.** *Science.* 2008; **322**(5904): 1097–100.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
18. Reis e Sousa C, Hieny S, Scharton-Kersten T, *et al.*: **In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas.** *J Exp Med.* 1997; **186**(11): 1819–29.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Mashayekhi M, Sandau MM, Dunay IR, *et al.*: **CD8alpha⁺ dendritic cells are the critical source of interleukin-12 that controls acute infection by *Toxoplasma gondii* tachyzoites.** *Immunity.* 2011; **35**(2): 249–59.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
20. den Haan JM, Lehar SM, Bevan MJ: **CD8⁺ but not CD8⁻ dendritic cells cross-prime cytotoxic T cells in vivo.** *J Exp Med.* 2000; **192**(12): 1685–96.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Murphy KM: **Transcriptional control of dendritic cell development.** *Adv Immunol.* 2013; **120**: 239–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Naik SH, Metcalf D, van Nieuwenhuijze A, *et al.*: **Intrasplenic steady-state dendritic cell precursors that are distinct from monocytes.** *Nat Immunol.* 2006; **7**(6): 663–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
23. Sallusto F, Lanzavecchia A: **Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.** *J Exp Med.* 1994; **179**(4): 1109–18.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Caux C, Dezutter-Dambuyant C, Schmitt D, *et al.*: **GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells.** *Nature.* 1992; **360**(6401): 258–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Inaba K, Inaba M, Romani N, *et al.*: **Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.** *J Exp Med.* 1992; **176**(6): 1693–702.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Helft J, Böttcher J, Chakravarty P, *et al.*: **GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous Population of CD11c⁺MHCII⁺ Macrophages and Dendritic Cells.** *Immunity.* 2015; **42**(6): 1197–211.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
27. Xu Y, Zhan Y, Lew AM, *et al.*: **Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking.** *J Immunol.* 2007; **179**(11): 7577–7584.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
28. Bevan MJ: **Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay.** *J Exp Med.* 1976; **143**(5): 1283–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Joffre OP, Segura E, Savina A, *et al.*: **Cross-presentation by dendritic cells.** *Nat Rev Immunol.* 2012; **12**(8): 557–69.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Pfeifer JD, Wick MJ, Roberts RL, *et al.*: **Phagocytic processing of bacterial antigens for class I MHC presentation to T cells.** *Nature.* 1993; **361**(6410): 359–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Kovacsics-Bankowski M, Clark K, Benacerraf B, *et al.*: **Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages.** *Proc Natl Acad Sci U S A.* 1993; **90**(11): 4942–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Kovacsics-Bankowski M, Rock KL: **A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules.** *Science.* 1995; **267**(5193): 243–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Briseño CG, Haldar M, Kretzer NM, *et al.*: **Distinct Transcriptional Programs Control Cross-Priming in Classical and Monocyte-Derived Dendritic Cells.** *Cell Rep.* 2016; **15**(11): 2462–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Naik SH, Proietto AI, Wilson NS, *et al.*: **Cutting edge: generation of splenic CD8⁺ and CD8⁻ dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures.** *J Immunol.* 2005; **174**(11): 6592–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Mayer CT, Ghorbani P, Nandan A, *et al.*: **Selective and efficient generation of functional Batf3-dependent CD103⁺ dendritic cells from mouse bone marrow.** *Blood.* 2014; **124**(20): 3081–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
36. Kamphorst AO, Guermónprez P, Dudziak D, *et al.*: **Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes.** *J Immunol.* 2010; **185**(6): 3426–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Kretzer NM, Theisen DJ, Tussiwand R, *et al.*: **RAB43 facilitates cross-presentation of cell-associated antigens by CD8⁺ dendritic cells.** *J Exp Med.* 2016; **213**(13): 2871–83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Brossart P, Bevan MJ: **Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines.** *Blood.* 1997; **90**(4): 1594–9.
[PubMed Abstract](#) | [Free Full Text](#)
39. Morón VG, Rueda P, Sedlik C, *et al.*: **In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway.** *J Immunol.* 2003; **171**(5): 2242–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Savina A, Jancic C, Hugues S, *et al.*: **NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells.** *Cell.* 2006; **126**(1): 205–18.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)

41. **F** Jancic C, Savina A, Wasmeier C, *et al.*: **Rab27a regulates phagosomal pH and NADPH oxidase recruitment to dendritic cell phagosomes.** *Nat Cell Biol.* 2007; **9**(4): 367–78.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
42. Savina A, Peres A, Cebrian I, *et al.*: **The small GTPase Rac2 controls phagosomal alkalization and antigen crosspresentation selectively in CD8⁺ dendritic cells.** *Immunity.* 2009; **30**(4): 544–55.
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Zou L, Zhou J, Zhang J, *et al.*: **The GTPase Rab3b/3c-positive recycling vesicles are involved in cross-presentation in dendritic cells.** *Proc Natl Acad Sci U S A.* 2009; **106**(37): 15801–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. Alloatti A, Kotsias F, Pauwels AM, *et al.*: **Toll-like Receptor 4 Engagement on Dendritic Cells Restrains Phago-Lysosome Fusion and Promotes Cross-Presentation of Antigens.** *Immunity.* 2015; **43**(6): 1087–100.
[PubMed Abstract](#) | [Publisher Full Text](#)
45. **F** Samie M, Cresswell P: **The transcription factor TFEB acts as a molecular switch that regulates exogenous antigen-presentation pathways.** *Nat Immunol.* 2015; **16**(7): 729–36.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
46. **F** Zehner M, Marschall AL, Bos E, *et al.*: **The translocon protein Sec61 mediates antigen transport from endosomes in the cytosol for cross-presentation to CD8⁺ T cells.** *Immunity.* 2015; **42**(5): 850–63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
47. Grommé M, Uytendaele FG, Janssen H, *et al.*: **Recycling MHC class I molecules and endosomal peptide loading.** *Proc Natl Acad Sci U S A.* 1999; **96**(18): 10326–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
48. Bertholet S, Goldszmid R, Morrot A, *et al.*: **Leishmania antigens are presented to CD8⁺ T cells by a transporter associated with antigen processing-independent pathway *in vitro* and *in vivo*.** *J Immunol.* 2006; **177**(6): 3525–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Saveanu L, Carroll O, Weimershaus M, *et al.*: **IRAP identifies an endosomal compartment required for MHC class I cross-presentation.** *Science.* 2009; **325**(5937): 213–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. **F** Serwold T, Gonzalez F, Kim J, *et al.*: **ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum.** *Nature.* 2002; **419**(6906): 480–3.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
51. Segura E, Albiston AL, Wicks IP, *et al.*: **Different cross-presentation pathways in steady-state and inflammatory dendritic cells.** *Proc Natl Acad Sci U S A.* 2009; **106**(48): 20377–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
52. **F** Weimershaus M, Maschalidi S, Sepulveda F, *et al.*: **Conventional dendritic cells require IRAP-Rab14 endosomes for efficient cross-presentation.** *J Immunol.* 2012; **188**(4): 1840–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
53. **F** Sancho D, Joffre OP, Keller AM, *et al.*: **Identification of a dendritic cell receptor that couples sensing of necrosis to immunity.** *Nature.* 2009; **458**(7240): 899–903.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
54. Schnorrer P, Behrens GM, Wilson NS, *et al.*: **The dominant role of CD8⁺ dendritic cells in cross-presentation is not dictated by antigen capture.** *Proc Natl Acad Sci U S A.* 2006; **103**(28): 10729–34.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
55. **F** Cebrian I, Visentin G, Blanchard N, *et al.*: **Sec22b regulates phagosomal maturation and antigen crosspresentation by dendritic cells.** *Cell.* 2011; **147**(6): 1355–68.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
56. **F** Nair-Gupta P, Baccarini A, Tung N, *et al.*: **TLR signals induce phagosomal MHC-I delivery from the endosomal recycling compartment to allow cross-presentation.** *Cell.* 2014; **158**(3): 506–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
57. **F** Basha G, Omilusik K, Chavez-Steenbock A, *et al.*: **A CD74-dependent MHC class I endolysosomal cross-presentation pathway.** *Nat Immunol.* 2012; **13**(3): 237–45.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
58. **F** Satpathy AT, KC W, Albring JC, *et al.*: **Zbtb46 expression distinguishes classical dendritic cells and their committed progenitors from other immune lineages.** *J Exp Med.* 2012; **209**(6): 1135–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
59. Hou W, Gibbs JS, Lu X, *et al.*: **Viral infection triggers rapid differentiation of human blood monocytes into dendritic cells.** *Blood.* 2012; **119**(13): 3128–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
60. **F** Langlet C, Tamoutounour S, Henri S, *et al.*: **CD64 expression distinguishes monocyte-derived and conventional dendritic cells and reveals their distinct role during intramuscular immunization.** *J Immunol.* 2012; **188**(4): 1751–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
61. Campbell IK, van Nieuwenhuijze A, Segura E, *et al.*: **Differentiation of inflammatory dendritic cells is mediated by NF- κ B1-dependent GM-CSF production in CD4 T cells.** *J Immunol.* 2011; **186**(9): 5468–77.
[PubMed Abstract](#) | [Publisher Full Text](#)
62. **F** Plantinga M, Guillems M, Vanheerswynghels M, *et al.*: **Conventional and monocyte-derived CD11b⁺ dendritic cells initiate and maintain T helper 2 cell-mediated immunity to house dust mite allergen.** *Immunity.* 2013; **38**(2): 322–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
63. Greter M, Helft J, Chow A, *et al.*: **GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells.** *Immunity.* 2012; **36**(6): 1031–46.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
64. **F** Gautier EL, Shay T, Miller J, *et al.*: **Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages.** *Nat Immunol.* 2012; **13**(11): 1118–28.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
65. Wu X, Briseño CG, Durai V, *et al.*: **Mafb lineage tracing to distinguish macrophages from other immune lineages reveals dual identity of Langerhans cells.** *J Exp Med.* 2016; **213**(12): 2553–65.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
66. Jakubczik C, Gautier EL, Gibbins SL, *et al.*: **Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes.** *Immunity.* 2013; **39**(3): 599–610.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
67. **F** Chow KV, Lew AM, Sutherland RM, *et al.*: **Monocyte-Derived Dendritic Cells Promote Th Polarization, whereas Conventional Dendritic Cells Promote Th Proliferation.** *J Immunol.* 2016; **196**(2): 624–36.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
68. Blum JS, Wearsch PA, Cresswell P: **Pathways of antigen processing.** *Annu Rev Immunol.* 2013; **31**: 443–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
69. Xu RH, Remakus S, Ma X, *et al.*: **Direct presentation is sufficient for an efficient anti-viral CD8⁺ T cell response.** *PLoS Pathog.* 2010; **6**(2): e1000768.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
70. Busche A, Jirmo AC, Welten SP, *et al.*: **Priming of CD8⁺ T cells against cytomegalovirus-encoded antigens is dominated by cross-presentation.** *J Immunol.* 2013; **190**(6): 2767–77.
[PubMed Abstract](#) | [Publisher Full Text](#)
71. **F** Snyder CM, Allan JE, Bonnett EL, *et al.*: **Cross-presentation of a spread-defective MCMV is sufficient to prime the majority of virus-specific CD8⁺ T cells.** *PLoS One.* 2010; **5**(3): e9681.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
72. **F** Heipertz EL, Davies ML, Lin E, *et al.*: **Prolonged antigen presentation following an acute virus infection requires direct and then cross-presentation.** *J Immunol.* 2014; **193**(8): 4169–77.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
73. **F** Eickhoff S, Brewitz A, Gerner MY, *et al.*: **Robust Anti-viral Immunity Requires Multiple Distinct T Cell-Dendritic Cell Interactions.** *Cell.* 2015; **162**(6): 1322–37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
74. Alexandre YO, Ghilas S, Sanchez C, *et al.*: **XCR1⁺ dendritic cells promote memory CD8⁺ T cell recall upon secondary infections with *Listeria monocytogenes* or certain viruses.** *J Exp Med.* 2016; **213**(1): 75–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
75. **F** Iborra S, Martínez-López M, Khouili SC, *et al.*: **Optimal Generation of Tissue-Resident but Not Circulating Memory T Cells during Viral Infection Requires Crosspriming by DNGR-1⁺ Dendritic Cells.** *Immunity.* 2016; **45**(4): 847–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
76. Edelson BT, Ko W, Juang R, *et al.*: **Peripheral CD103⁺ dendritic cells form a unified subset developmentally related to CD8 α ⁺ conventional dendritic cells.** *J Exp Med.* 2010; **207**(4): 823–36.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
77. Allan RS, Waithman J, Bedoui S, *et al.*: **Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming.** *Immunity.* 2006; **25**(1): 153–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
78. **F** Hor JL, Whitney PG, Zaid A, *et al.*: **Spatiotemporally Distinct Interactions with Dendritic Cell Subsets Facilitates CD4⁺ and CD8⁺ T Cell Activation to Localized Viral Infection.** *Immunity.* 2015; **43**(3): 554–65.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
79. **F** Bedoui S, Whitney PG, Waithman J, *et al.*: **Cross-presentation of viral and self antigens by skin-derived CD103⁺ dendritic cells.** *Nat Immunol.* 2009; **10**(5): 488–95.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
80. **F** Kitano M, Yamazaki C, Takumi A, *et al.*: **Imaging of the cross-presenting dendritic cell subsets in the skin-draining lymph node.** *Proc Natl Acad Sci U S A.* 2016; **113**(4): 1044–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
81. **F** Wakim LM, Bevan MJ: **Cross-dressed dendritic cells drive memory CD8⁺ T-cell activation after viral infection.** *Nature.* 2011; **471**(7340): 629–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
82. Bennett SR, Carbone FR, Karamalis F, *et al.*: **Induction of a CD8⁺ cytotoxic**

T lymphocyte response by cross-priming requires cognate CD4⁺ T cell help. *J Exp Med.* 1997; **186**(1): 65–70.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

83. **F** Wang Y, Swiecki M, Cella M, *et al.*: **Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection.** *Cell Host Microbe.* 2012; **11**(6): 631–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
84. Bennett SR, Carbone FR, Karamalis F, *et al.*: **Help for cytotoxic-T-cell responses is mediated by CD40 signalling.** *Nature.* 1998; **393**(6684): 478–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
85. Ridge JP, Di Rosa F, Matzinger P: **A conditioned dendritic cell can be a temporal bridge between a CD4⁺ T-helper and a T-killer cell.** *Nature.* 1998; **393**(6684): 474–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
86. Schoenberger SP, Toes RE, van der Voort EI, *et al.*: **T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.** *Nature.* 1998; **393**(6684): 480–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
87. **F** Dudziak D, Kamphorst AO, Heidkamp GF, *et al.*: **Differential antigen processing by dendritic cell subsets *in vivo*.** *Science.* 2007; **315**(5808): 107–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
88. **F** Gerner MY, Torabi-Parizi P, Germain RN: **Strategically localized dendritic cells promote rapid T cell responses to lymph-borne particulate antigens.** *Immunity.* 2015; **42**(1): 172–85.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
89. Ferris ST, Carrero JA, Mohan JF, *et al.*: **A minor subset of *Batf3*-dependent antigen-presenting cells in islets of Langerhans is essential for the development of autoimmune diabetes.** *Immunity.* 2014; **41**(4): 657–69.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
90. **F** Ohta T, Sugiyama M, Hemmi H, *et al.*: **Crucial roles of XCR1-expressing dendritic cells and the XCR1-XCL1 chemokine axis in intestinal immune homeostasis.** *Sci Rep.* 2016; **6**: 23505.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
91. Heng TS, Painter MW: **The Immunological Genome Project: networks of gene expression in immune cells.** *Nat Immunol.* 2008; **9**(10): 1091–4.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Paul Roche**

Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Competing Interests: No competing interests were disclosed.

2. **Terri M. Laufer**

¹ Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

² Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA

Competing Interests: No competing interests were disclosed.

3. **Caetano Reis e Sousa**

Immunobiology Laboratory, The Francis Crick Institute, London, UK

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research